![](https://webarchive.library.unt.edu/eot2008/20081025040544im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081025040544im_/http://www.cancer.gov/images/spacer.gif)
siplizumab A monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20081025040544im_/http://www.cancer.gov/images/spacer.gif)
Synonym: | ![](https://webarchive.library.unt.edu/eot2008/20081025040544im_/http://www.cancer.gov/images/spacer.gif) | anti-CD2 monoclonal antibody | | ![](https://webarchive.library.unt.edu/eot2008/20081025040544im_/http://www.cancer.gov/images/spacer.gif) | Code name: | ![](https://webarchive.library.unt.edu/eot2008/20081025040544im_/http://www.cancer.gov/images/spacer.gif) | MEDI-507 | | ![](https://webarchive.library.unt.edu/eot2008/20081025040544im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081025040544im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081025040544im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081025040544im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081025040544im_/http://www.cancer.gov/images/spacer.gif) |